Record mula sa primary source
Inuulit ng earnings release na ito ang pagkumpleto ng pagpapatala sa unang cohort ng Phase 2 renal basket study ng vensobafusp alfa (KP104) sa mga pasyente na may IgA nephropathy. Plano ng kumpanya na iulat ang interim data sa Q4 2026 at na-update na data sa Q1 2027. Binanggit din nito ang pagsisimula ng pagpapatala sa IC-MPGN cohort at pagbubukas ng FSGS expansion cohort na may unang dosing na inaasahang mangyari sa Q1 2027.
EX-99.1 2 ea031213401ex99-1.htm PRESS RELEASE, DATED NOVEMBER 16, 2026 Exhibit 99.1 Jasper Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update REDWOOD CITY, Calif., November 16, 2026 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today reported results for the fiscal quarter ended September 30, 2026, and provided a corporate update. “We have made progress advancing our development programs in recent months following our acquisition of Kira Pharmaceuticals, highlighted by the recent completion of enrollment in the first cohort of our Phase 2 renal basket study evaluating vensobafusp alfa (KP10
Nakumpleto ng Jasper Therapeutics ang Pagpapatala sa IgAN Cohort sa Phase 2 Basket Study ng Vensobafusp Alfa (KP104)